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CRISPR-Trap: a clean approach for the 
generation of gene knockouts and gene 
replacements in human cells
ABSTRACT CRISPR/Cas9-based genome editing offers the possibility to knock out almost 
any gene of interest in an affordable and simple manner. The most common strategy is the 
introduction of a frameshift into the open reading frame (ORF) of the target gene which trun-
cates the coding sequence (CDS) and targets the corresponding transcript for degradation by 
nonsense-mediated mRNA decay (NMD). However, we show that transcripts containing pre-
mature termination codons (PTCs) are not always degraded efficiently and can generate C-
terminally truncated proteins which might have residual or dominant negative functions. 
Therefore, we recommend an alternative approach for knocking out genes, which combines 
CRISPR/Cas9 with gene traps (CRISPR-Trap) and is applicable to ∼50% of all spliced human 
protein-coding genes and a large subset of lncRNAs. CRISPR-Trap completely prevents the 
expression of the ORF and avoids expression of C-terminal truncated proteins. We demon-
strate the feasibility of CRISPR-Trap by utilizing it to knock out several genes in different 
human cell lines. Finally, we also show that this approach can be used to efficiently generate 
gene replacements allowing for modulation of protein levels for otherwise lethal knockouts 
(KOs). Thus, CRISPR-Trap offers several advantages over conventional KO approaches and 
allows for generation of clean CRISPR/Cas9-based KOs.
INTRODUCTION
A decade ago, zinc-fingers, the first customizable site-directed en-
donucleases, were shown to allow for targeted genome editing in 
human cells (Urnov et al., 2005). During the past 10 yr, genome edit-
ing approaches have rapidly evolved, leading to the development 
of TALENs (Christian et al., 2010) and the CRISPR/Cas9 technology 
(Cong et al., 2013; Mali et al., 2013). Among all gene-targeting 
strategies, CRISPR/Cas9 is the most versatile tool. Owing to its 
modularity—changing only the single guide RNA (sgRNA) sequence 
is sufficient to target the Cas9 endonuclease to any desired se-
quence—CRISPR/Cas9 has become one of the most popular tech-
nologies within today’s biotechnology (Jinek et al., 2012; Cong 
et al., 2013; Mali et al., 2013; Du et al., 2016).
A commonly used strategy to generate gene knockouts (KOs) is to 
target the coding sequence (CDS) of the gene of interest with CRISPR/
Cas9. Upon cleavage by Cas9, one of the two major DNA damage 
repair pathways usually repairs the double-strand break (DSB); either 
the accurate homology-directed repair (HDR) pathway or the error-
prone nonhomologous end joining (NHEJ). NHEJ typically leads to 
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C-terminally truncated FUS protein in some of the clones, whereas 
there was hardly any mRNA expression and no C-terminally trun-
cated FUS detectable in other clones (Figure 1, A and B). To ensure 
that this behavior was restricted neither to transcripts of the FUS 
gene nor to human cell lines, we analyzed available data sets where 
gene KOs were obtained by introduction of frameshift mutations 
into the CDS, followed by a whole transcriptome analysis (Huang 
et al., 2013; Richter et al., 2013; Kabir et al., 2014; McCleland et al., 
2015; Sadic et al., 2015; Kim et al., 2016; Lebedeva et al., 2016). In 
line with our observation, 12–73% mRNA of the KO targets were still 
detectable in these studies (Supplemental Table S1).
RNA and protein levels of predicted NMD targets
To address the dependency of mRNA and protein levels of pre-
dicted NMD targets on the position of the stop codon within the 
transcript, we generated a series of reporter constructs (Figure 2A) 
based on the immunoglobulin (Ig) µ minigene (mini-µ) reporter sys-
tem (Buhler et al., 2004). Every reporter plasmid codes for Ig µ (in-
cluding intronic sequences) under a cytomegalovirus promoter with 
a termination codon at a specific position of the open reading frame 
(referred to as TER[number] indicating the amino acid position of 
small insertions/deletions in the vicinity of the DSB, often resulting in 
a frameshift and generation of a premature termination codon (PTC; 
Ran et al., 2013). Owing to the truncated CDS, the corresponding 
mRNA is predicted to be recognized by the nonsense-mediated 
mRNA decay (NMD) pathway, which degrades transcripts harboring 
PTCs in a translation-dependent manner (Karousis et al., 2016) and 
therefore should result in a de facto KO. However, NMD does not 
target all PTC-containing transcripts with the same efficacy for degra-
dation. The position of the PTC within the transcript (Eberle et al., 
2008; Neu-Yilik et al., 2011) and the sequence composition around 
the termination codon (Loughran et al., 2014) strongly influence the 
sensitivity of a transcript to NMD. Indeed, different transcripts pre-
dicted to be degraded by NMD, some of which were implicated in 
disease, were shown to escape NMD and in some cases the corre-
sponding truncated protein is detectable (Green et al., 2003; Littink 
et al., 2009; Malfatti et al., 2015). Consequently, transcripts harboring 
frameshift mutations mediated by CRISPR/Cas9 may give rise to C-
terminally truncated proteins, which could have residual or dominant 
negative functions. Even though it remains to be elucidated whether 
C-terminally truncated proteins affect functional studies in cell culture 
and/or animal models, their occurrence and physiological impact 
should be considered, especially in the context of clinical trials. In-
deed, the first clinical trial testing CRISPR/Cas9 to knock out PDCD1 
(programmed cell death 1) in immune cells of cancer patients started 
last year in China and similar trials are planned in the United States 
(Cyranoski, 2016).
Here, we propose a clean approach to knock out genes in hu-
man cell lines by combining gene traps with CRISPR/Cas9 technol-
ogy targeting the first intron of genes of interest. Gene traps have 
been used for almost 20 yr for the generation of transgenic animals 
(Stanford et al., 1998) but rely on spontaneously occurring HDR, a 
very rare event. CRISPR-Trap, however, bypasses this limitation and 
allows flexible and efficient generation of gene KOs. Most impor-
tant, however, CRISPR-Trap results in the complete abrogation of 
the corresponding full-length transcript, thereby preventing C- 
terminally truncated proteins and is directly applicable to ≈50% of 
all spliced human protein-coding genes and potentially all spliced 
RNA Pol II transcripts, if the first exon is directly targeted. Further-
more, the approach also allows for gene replacements using the 
same sgRNA. Additionally, we investigate the dependency of pro-
tein and RNA levels on the position of a PTC within a transcript us-
ing HEK-293 Flp-In T-REx cells stably expressing human β-globin 
(HBB) reporter constructs as well as HeLa cells transiently express-
ing a mini-µ reporter construct. Our results highlight the impor-
tance of a well-considered design and thorough analysis of CRISPR/
Cas9-created gene KOs.
RESULTS AND DISCUSSION
Residual mRNA and truncated protein expression in KO cell 
lines with frameshift mutations
While establishing a human-induced pluripotent stem cell (hiPSC) 
line harboring a missense mutation in the fifth exon of the fused in 
sarcoma (FUS) gene, we obtained different clones with frameshift 
mutations in the targeted exon (Supplemental Figure S1). Based on 
the position of the PTCs within these transcripts, they were pre-
dicted to be ideal targets for NMD. The PTCs were positioned 
>50–55 nucleotides upstream of the 3′ most exon-exon junction, 
which is a strong trigger of NMD (Schweingruber et al., 2013), and 
they were located neither close to the 5′ nor to the 3′ end of the 
transcripts, a feature that was shown to stabilize PTC-containing 
transcripts (Eberle et al., 2008). Hence, we assumed to have created 
FUS KO cell lines. Intriguingly, we could detect mRNA, as well as 
FIGURE 1: Residual mRNA and C-terminally truncated FUS protein 
expression in cell lines with FUS frameshift mutations. (A) FUS mRNA 
levels of two frameshift clones (fs1 and fs2) and one hiPSC line with a 
homozygous in-frame deletion in exon 5 of the FUS gene relative to 
wild-type FUS mRNA expression as determined by RT-qPCR. Average 
values and standard deviations of three biological replicates are 
shown. (B) Western blot confirming the absence of FUS protein in 
clone fs1 and showing the C-terminally truncated FUS in clone fs2 
(indicated with a black arrow). For better visualization of the band 
indicated with the black arrow, this section of the Western blot is 
displayed with a higher exposure (lower membrane part labeled with 
α-FUS). The asterisk indicates an unspecific band recognized by the 
α-FUS antibodies equally present in all samples. SmB/B′ served as a 
loading control.
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reported that short peptides are difficult to detect by classical West-
ern blotting (Schagger, 2006; Tomisawa et al., 2013). Indeed, al-
ready the TER100 construct was undetectable (Supplemental Figure 
S2A). We therefore reasoned that the TER30 peptide is most likely 
synthesized, but too small for detection by slot blotting. In support 
of this, we could detect expression of the TER30 constructs by im-
munofluorescence microscopy (Supplemental Figure S2B). Collec-
tively, these data indicate that short peptides produced from PTC-
containing mRNAs are not necessarily degraded. Consequently, 
their absence on Western blots, the standard method to analyze 
protein abundances, is rather explained by a detection problem 
than by the physical absence of the peptide.
As a complementary approach to study protein production from 
NMD-sensitive transcripts, we generated HEK-293 Flp-In T-REx cells 
stably expressing 3xFLAG-tagged (N-term) human β-globin (HBB) 
with (PTC+) or without (PTC−) a PTC at amino acid position 39 of the 
HBB CDS (Supplemental Figure S2C). The Flp-In T-REx system al-
lows for the introduction of a gene of interest at a specific locus and 
the TERmination codon). To enable immunodetection, a 2xHA-tag 
was cloned in front of the CDS, replacing the variable leader exon of 
the Ig µ minigene. Reporter plasmids harboring PTCs at different 
positions within the open reading frame (ORF) were transiently 
transfected into HeLa cells. Protein and mRNA levels were assessed 
by slot blotting and real-time quantitative PCR (RT-qPCR), respec-
tively (Figure 2, A and B). In agreement with previous data (Eberle 
et al., 2008), stop codons proximal to the 5′ and the 3′ ends of the 
transcript only moderately reduced its stability, whereas stop co-
dons more distal to the ends of the mRNA induced its degradation 
(Figure 2A, black line). Proteins produced from transcripts harboring 
a stop codon closer to the 3′ end of CDS correlated well with the 
corresponding mRNA level. On the other hand, only a low level of 
protein could be detected for transcripts with a very short ORF 
(Figure 2A, green line). This discrepancy is likely because the pep-
tides produced from the TER30 reporter construct are rapidly de-
graded after their synthesis or because they are too short to be ef-
ficiently detected using slot blots. Notably, it was previously 
FIGURE 2: RNA and protein levels of predicted NMD targets. (A) mRNA levels and protein levels of mini-µ reporter 
constructs each containing a PTC at the indicated positions relative to the wild-type construct (stop codon at amino acid 
position 600). All reporters consist of five exons and four introns (not shown) and encode a 2xHA-tag at their 
N-terminus. Positions of the stop codons of the different reporters and the exon-exon boundaries (dark lines 
interrupting the green bar representing the mini-µ reporter gene), identical to all transcripts, are indicated. mRNA and 
protein levels were determined by RT-qPCR and slot blotting, respectively. Average values and standard deviations of 
three biological replicates are shown. (B) Representative slot blot displaying the protein expression levels of different 
reporter constructs detected by anti-HA antibodies (green) and CPSF-100 (red, loading control). A nontransfected 
control (NTC) was used to estimate the background signal. The last column shows the overlay. (C) HBB PTC−/+ reporter 
constructs were immunoprecipitated from total cell extracts after 24 h of induction with 250 ng/ml doxycycline. Purified 
proteins were separated by Nu–PAGE and the gel subjected to silver staining. Both reporter constructs are detectable. 
(D) Western blot of total cell extracts from C (input) and of the corresponding immunoprecipitations (IP).
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replaced. Furthermore, cells with off-target integrations of the cas-
sette will not survive the selection, due to the absence of a promoter 
and hence lack of transcription of the selection marker. Because this 
approach allows targeting of potentially every spliced transcript, it 
also allows knocking out or replacing a large subset of long noncod-
ing RNAs (lncRNAs).
Following this strategy, we successfully introduced a FUS KO in 
SH-SY5Y neuroblastoma cells (Reber et al., 2016) as well as in HeLa 
and hiPSCs (Figure 4, A and B). Although the FUS gene has a coding 
first exon, our approach is still applicable. The first exon of FUS en-
codes only four amino acids. Therefore, we designed a cassette that 
is spliced in frame with the first four codons of FUS, hijacking the 
endogenous start codon to instead express the selection marker, a 
zeocin resistance (Reber et al., 2016). Apart from the FUS gene, we 
applied CRISPR-Trap to knock out the SMG7 gene in HT1080 cells 
and validated the absence of both the protein (by Western blot; 
Figure 4C) and the corresponding transcript (by RNA deep sequenc-
ing; Figure 4D). Importantly, a direct comparison of SMG7 CRISPR-
Trap to frameshift-based KOs exemplifies the advantage of CRISPR-
Trap: a frameshift clone in exon 3 expresses a high amount of SMG7 
mRNA and frameshifts in exon 15 even result in the expression of a 
truncated SMG7 protein detectable by Western blot (Supplemental 
Figure S3).
CRISPR-Trap can be used both to create gene KOs and to gener-
ate gene replacements. The latter approach is of particular interest 
when studying essential genes where complete KOs are lethal. As a 
proof of principle, we targeted the TARDBP gene where conditional 
KO leads to death in both mice and mouse embryonic stem cells 
(Chiang et al., 2010). We performed the gene replacement in hiP-
SCs by introducing a cassette expressing the protein product of the 
TARDBP gene (TDP-43), N-terminally fused to the destabilizing do-
main (DD) of mutant human FKBP12 protein (Banaszynski et al., 
2006). In addition, the replacement cassette contains an internal ri-
bosomal entry site (IRES) and a puromycin resistance downstream 
from the DD-TDP-43 ORF allowing selection of successfully edited 
clones. The DD targets the DD-TDP-43 fusion protein for rapid deg-
radation through the proteasome (Figure 5A). The fusion protein is 
its inducible expression upon addition of tetracycline (or doxycy-
cline) to the culture medium. Expression of both constructs was in-
duced with doxycycline for 24 h before harvesting. As measured by 
RT-qPCR, HBB PTC+ mRNA levels were significantly decreased 
when compared with HBB PTC- mRNA (Supplemental Figure S2D). 
To monitor protein levels, we performed affinity purification using 
M2 anti-FLAG antibodies, separated purified proteins by gel elec-
trophoresis, and visualized these by silver staining and Western 
blotting. Importantly, the same gel system and protein ladder were 
used for either approach. Intriguingly, both the full-length HBB 
PTC− and its truncated version HBB PTC+ were detected directly in 
the gel after silver staining (Figure 2C). Staining intensity, although 
only semiquantitative, indicates that the HBB PTC+ peptide is less 
abundant when compared with the truncated HBB PTC− version. In 
contrast, only the full-length HBB PTC− was detectable by Western 
blotting (Figure 2D), emphasizing the fact that short peptides are 
problematic to detect using the latter approach.
CRISPR-Trap; merging CRISPR/Cas9, targeting the first 
intron with gene traps
In consequence of our findings, we next aimed to establish a gene-
targeting approach that would completely abolish expression of full-
length transcripts of targeted genes. To this end, we merged 
CRISPR/Cas9 technology, targeting the first intron of genes of inter-
est, with a gene trap introduced through HDR from a donor plasmid. 
The gene trap consists of a chimeric intron with a 3′ splice site pre-
ceding a customizable cassette (containing, e.g., a selection marker) 
and a polyadenylation signal (Figure 3A). Our CRISPR-Trap ap-
proach can be applied to 1) gene KO, resulting in a premature tran-
scription termination within the first intron of the targeted gene and 
expression of the selection marker under the promoter of the tar-
geted gene, and 2) gene replacement, allowing for simultaneous 
expression of a modified gene and a selection marker (Figure 3A). 
Importantly, CRISPR-Trap is directly applicable to almost 50% of all 
human protein-coding intron-containing genes because these have 
a noncoding first exon (Figure 3B). In that case, only the homology 
arms of the donor plasmid and the sgRNA sequence need to be 
FIGURE 3: CRISPR-Trap. (A) Scheme of the CRISPR-Trap gene-targeting strategy. Cleavage of the first intron of the 
gene of interest is mediated by CRISPR/Cas9. A donor matrix serves as a template for HDR and is inserted into the first 
intron. The insert consists of a chimeric intron with a 3′ splice site (dark blue) followed by a customizable cassette (blue) 
and a SV40 polyadenylation signal (light blue) to terminate transcription in the first intron. The customizable cassette 
can either mediate a gene KO (left) or a gene replacement (right). Both strategies rely on a selection marker expressed 
under the promoter of the gene of interest after successful gene targeting. For the latter strategy, the translation of the 
selection marker depends on an IRES upstream of its CDS. (B) Histogram summarizing the number of amino acids 
(x-axis) encoded by all known human spliced protein-coding genes (RefSeq release 78). On the y-axis, relative 
contribution of each bin to the genome is depicted. Note that almost half of all human intron-containing genes have a 
noncoding first exon.
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and macular degeneration (Gough et al., 2012). Finally, the mu-
tated mRNA itself can have deleterious side effects, as alterations 
in mRNA secondary structures caused by indels have been associ-
ated with diseases (Zhang et al., 2014).
CRISPR-Trap, however, can bypass these pitfalls. It enables a 
complete elimination of the full-length transcript, either by hijacking 
or replacing the endogenous ORF, and consequently prevents the 
expression of unwanted and potentially problematic genome edit-
ing byproducts.
MATERIALS AND METHODS
Oligonucleotides, plasmids, antibodies, computational 
analysis of publicly available data sets
Used oligonucleotides, plasmids, antibodies, and computational 
analysis of publicly available data sets are described in the Supple-
mental Material.
Cell culture
Cells were maintained in DMEM+/+ containing 10% fetal calf serum 
(FCS), penicillin (100 U/µl), and streptomycin (100 µg/ml) at 37°C 
and 5% CO2. HeLa, HEK293T, and HT1080 cells were kindly pro-
vided by Oliver Mühlemann (University of Bern). The HEK293 Flp-In 
T-REx cell line was from Thermo Fisher Scientific. The human iPSC 
line iPS DF6-9-9T.B was purchased from WiCell (Yu et al., 2009). The 
SH-SY5Y and FUS KO SH-SY5Y cell lines were previously described 
(Reber et al., 2016). All cell stocks were tested for Mycoplasma 
stable only in the presence of Shield1 ligand bound to the DD. 
Withdrawal of the ligand from the culture medium leads to the deg-
radation of the fusion protein within a few hours (Banaszynski et al., 
2006; Maynard-Smith et al., 2007). We validated the successful in-
troduction of the cassette into hiPSCs by PCR of the corresponding 
genomic locus (Figure 5B) and demonstrated the efficient degrada-
tion of DD-TDP-43 after removal of the ligand (Figure 5C).
Conclusion
In summary, we show that early truncation of an ORF using gene-
targeting approaches often results in inefficient degradation of the 
corresponding mRNA and production of C-terminally truncated 
proteins. Moreover, we observe that such peptides are difficult to 
detect and are most likely missed using classical Western blotting 
approaches. However, their appearance and potential biological 
consequences have to be considered, especially in the context of 
future gene KO approaches using CRISPR/Cas9 for the treatment 
of human diseases. Additionally, with cellular differences in tran-
scription and protein turnover it is unforeseeable in which cell 
types and to what extent these peptides could exert unwanted 
functions (Kristensen et al., 2013; Buszczak et al., 2014). Further-
more, nonsense mutations occurring after structural domains are 
expected to yield stable truncations and in the cases where the 
PTC-containing transcripts are not subjected to NMD, these trun-
cations are associated with aggregation and diseases such as cor-
onary artery disease, non-Hodgkin lymphoma, cardiomyopathy, 
FIGURE 4: Generation and characterization of different KO cell lines. (A) RT-qPCR of FUS KO HeLa, SH-SY5Y, and 
hiPSCs shows the complete absence of the FUS transcript compared with the wild-type cells. Average values and 
standard deviations of three biological replicates are shown. (B) Western blot confirming the absence of FUS protein in 
the KO cell lines. Tyrosine tubulin served as a loading control. (C) Western blot showing SMG7 protein levels in WT 
HT1080 and SMG7 KO clones 11 and 12. The SMG7 blot shows one unspecific band marked with an asterisk and is 
already documented in Metze et al. (2013) and Colombo et al. (2017). CPSF-73 served as a loading control. (D) SMG7 
coverage plot: the coverage of mapped reads from RNA deep sequencing on the SMG7 locus is shown. Introns are 
reduced in length by a factor of 10 compared with exons for better visualization.
80 | S. Reber, J. Mechtersheimer, et al. Molecular Biology of the Cell
Gene 6000 R Corbett (Qiagen). Analysis of 
the qPCR results was conducted as previ-
ously described (Metze et al., 2013). Prim-
ers and 5′-FAM, 3′-BHQ1 labeled TaqMan 
probe sequences used in this study for de-
tection of HBB are listed in the Supplemen-
tal Materials and Methods.
Immunoprecipitation of 
3xFLAG-tagged HBB
HEK-293 Flp-In T-REx cells (5 × 106) express-
ing 3xFLAG-tagged HBB were seeded on 
T150 flasks. The following day, the cells 
were induced with 250 ng/ml doxycycline 
hyclate. After 24 h of induction, the cells 
were harvested by trypsination, washed 
once in PBS, and resuspended in 500 µl ex-
traction buffer (300 mM NaCl, 0.5% NP-40, 
20 mM HEPES, pH 7.4, supplemented with 
1× protease inhibitor cocktail (B14001; 
Biotool). The cells were then sonicated 3 × 
5 s, amplitude 45% (Vibracell 75186 sonica-
tor) with cooling on ice in between each 
cycle. The lysate was centrifuged for 10 min 
at 16,100 × g at 4°C. Clarified supernatant 
was incubated with 7.5 µl anti-FLAG beads 
for 1 h head over tail at 4°C. The beads 
were then washed once with 1 ml extraction 
buffer, followed by resuspension in 500 µl 
extraction buffer supplemented with 10 µl 
of 20 mg/ml RNase A (R6148; Sigma- 
Aldrich) and incubated head over tail for 
10 min at room temperature. Subsequently, 
the beads were washed with 2 × 1 ml extrac-
tion buffer. Proteins were eluted from the 
beads by adding 95 µl of 1.5 × LDS sample 
buffer (NP0008; Thermo Fisher) and incu-
bated for 10 min at 75°C. Before loading 
the eluates on gel, they were supplemented with 50 mM dithioth-
reitol (DTT) f.c. and incubated for 10 min at 75°C.
Coupling of anti-FLAG antibodies to Dynabeads 
M-270 epoxy
M2 anti-FLAG antibodies (F3165; Sigma-Aldrich) were conjugated 
to Dynabeads M-270 epoxy (14302D; Thermo Fisher Scientific) ac-
cording to the manufacturer’s instructions. For the coupling reaction, 
10 µg of anti-FLAG antibodies per 1 mg (dry weight) of Dynabeads 
M-270 epoxy were used. Before coupling, magnetic beads were 
washed twice with 1 ml of 0.1 M sodium phosphate buffer, pH 7.4. 
After the second wash, the coupling solution (1 M ammonium sul-
fate, 0.1 M sodium phosphate buffer, pH 7.4, antibodies) was added 
(20 µl per 1 mg beads). Conjugation was carried out overnight, at 
37°C with mixing at 1400 rpm (Eppendorf Thermomixer Comfort). 
Coupled beads were washed three times with 1 ml PBS, once with 1 
ml 0.5% Triton X-100 in PBS, followed by a final wash with 1 ml PBS 
and then stored at −20°C in 50% glycerol in PBS until use.
Silver staining
Proteins were separated on a NuPAGE 4–12% Bis-Tris Midi Gel 
(WG1403BOX; Thermo Fisher Scientific) using 1× MES running 
buffer. After electrophoresis, the gel was incubated overnight in 
fixing solution (50% MeOH, 12% HAc, 0.05% Formalin). The next 
contamination and were Mycoplasma-negative. Human iPSCs were 
maintained on Matrigel-coated plates (Corning) in mTeSR1 (Stem-
cell Technologies) and grown under hypoxic conditions (5% O2), 5% 
CO2 and 37°C. 200 nM Shield1 ligand (632189; Takara) was added 
to the stem cell medium when endogenous TDP-43 was replaced 
with DD-TDP-43. If not indicated, plasmid DNA transfections were 
performed using Dogtor (OZ Biosciences) for HeLa and HEK293T, 
TransIT-LT1 (Mirus Bio) for HT1080, and hiPSCs or Lipofectamine 
3000 reagent (Thermo Fisher) for SH-SY5Y and hiPSCs, respectively, 
according to the manufacturer’s instructions.
RT-qPCR
Cells were harvested by trypsination (HeLa, HEK-293 Flp-In T-REx, 
SH-SY5Y neuroblastoma, and HT1080) or with 0.5 mM EDTA in 
phosphate-buffered saline (PBS; hiPSCs). RNA was extracted using 
TRIzol (Marquis et al., 2009) and reverse transcribed. The RT-qPCR 
was performed as described in Raczynska et al. (2015). For cells 
expressing mini-µ reporter constructs, RNA was isolated and 
DNase treated using the GenElute Mammalian Total RNA Mini-
prep Kit (RTN350; Sigma-Aldrich) following the manufacturer’s in-
structions. After reverse transcription, qPCR was performed with 
Takyon for Probe Assay–No Rox MasterMix (UF-NPCT-B0205; Eu-
rogentec) or with MESA GREEN qPCR MasterMix Plus for SYBR 
Assay No ROX (05-SY2X-06+NRWOU; Eurogentec) on a Rotor-
FIGURE 5: Replacing TDP-43 with DD-TDP-43. (A) Scheme of the gene replacement strategy 
for the TARDBP gene (TDP-43). After successful genome editing, transcription of TARDBP is 
terminated within its first intron. The first exon is spliced to the cassette which codes for the DD-
TDP-43 fusion protein followed by an IRES allowing simultaneous expression of a puromycin 
resistance marker (PuroR). After translation, DD-TDP-43 is only stable in the presence of Shield1 
ligand. In absence of Shield1 ligand, DD-TDP-43 is rapidly degraded by the proteasome. Primers 
used to analyze the TARDBP genomic locus in B are indicated. (B) PCR of the genomic locus of 
WT hiPSCs and cells edited on two (homozygous) or one (heterozygous) allele, respectively. 
Primers aligned to TARDBP in A indicate the expected products. (C) Western blot showing 
successful replacement of TDP-43 by DD-TDP-43. Wild-type, mono- and biallelic edited cells 
were grown in the presence or absence (withdrawal 24 h before harvest) of Shield1 ligand. 
SmB/B′ served as a loading control.
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a Leica DMI6000 B microscope. Analysis was performed with LAS 
AF software (Leica Biosystems).
Human iPSC clones with mutations in FUS exon 5
Three 80% confluent hiPSC wells of a six-well plate were transfected 
using TransIT-2020 (MIR 5404; Mirus Bio) according to the manufac-
turer’s manual. Each transfection consisted of two plasmids coding 
for a TALEN binding upstream (left TALEN, pTAL EF1a 023977) and 
downstream (right TALEN, pTAL EF1a 021443), a donor plasmid 
(pCLS22315) for HDR, and a FUS exon 5 reporter plasmid according 
to Flemr and Buhler (2015). The vectors were transfected in a ratio 
of 2:2:1.25:1 (left TALEN to right TALEN to donor to reporter). A 
total of 2500, 5000, or 7100 ng of plasmid DNA was transfected 
on the three wells. Two days after transfection, cells were pooled 
with Accutase (Thermo Fisher) to generate single cells. Cells were 
maintained in mTeSR1 containing 10 µM of the ROCK inhibitor 
Y-27632 (Stemcell Technologies) to enhance single-cell survival. Two 
days later, puromycin selection (0.5 µg/ml) was started and main-
tained for 2 d. Colonies originating from single cells were picked 
and analyzed. RNA and genomic DNA were harvested from TRIzol. 
FUS expression was analyzed by RT-qPCR and the respective 
genomic locus was amplified by PCR using the KAPA Taq ReadyMix 
(KK1006; KAPA Biosystems) according to the manufacturer’s instruc-
tions. Primers are presented in the Supplemental Materials and 
Methods. PCR products were purified over a preparative agarose 
gel using the Wizard SV Gel and PCR Clean-Up System (A9281; 
Promega) and sent for Sanger sequencing (Barcode Economy Run 
Sequencing Service; Microsynth AG). To determine the genomic 
sequence of clones with different mutations in the two alleles, PCR 
products were TOPO-TA cloned into the pCRII-TOPO plasmid 
(K4610-20; Thermo Fisher) according to the manufacturer’s manual. 
Plasmids were subsequently amplified and purified from single 
Escherichia coli colonies and sent for sequencing.
Generation of HEK-293 Flp-In T-REx cells expressing 
3xFLAG-tagged HBB
The HBB coding sequence (including introns) was PCR-amplified 
(primer sequenced in the Supplemental Materials and Methods) 
and cloned into the pcDNA5/FRT/TO 3xFLAG (N) vector using 
HindIII and NotI restriction sites. The same strategy was applied for 
the PTC-containing HBB (TER39), resulting in the construct encod-
ing for 3xFLAG HBB with the stop codon at position 64. HEK293 
Flp-In T-REx cells expressing 3xFLAG-tagged (N-term) HBB were 
established according to the manufacturer’s instructions (Flp-In T-
Rex; Thermo Fisher Scientific). Briefly, 2 × 106 cells were seeded in 
10 ml DMEM (10% FCS, no P/S) on a 100 mm dish. The next day, 
cells were transfected (20 µl Lipofectamine 2000 in 500 µl Opti-
MEM, mixed with 18 µg of pOG44 and 2 µg pcDNA5/FRT/TO in 
500 µl Opti-MEM). After 24 h, cells were trypsinized, transferred to 
a T-175 flask, and cultured in DMEM (10% FCS, no P/S) until at-
tached (3 h) followed by the addition of selection medium (DMEM 
10% FCS, 1 × P/S, 100 µg/ml Hygromycin B and 10 µg/ml Blastici-
dine S). Cells were kept under selection until antibiotic-resistant 
colonies appeared. The colonies were trypsinized, triturated into a 
single-cell suspension, transferred to T-75 flask, and cultured in se-
lection medium until 90% confluency. After that, cells were split and 
kept in culture without any selection before the experiments.
Generation of FUS KO HeLa, SH-SY5Y neuroblastoma, 
and hiPSC cells
The FUS KO SH-SY5Y cell line was previously described (Reber et al., 
2016). FUS KO HeLa and hiPSC cells were generated following the 
day the gel was sequentially washed 3 × 20 min in 35% EtOH, 
sensitized in 0.02% Na2S2O3 for 2 min, washed 3 × 5 min in H2O, 
incubated for 20 min in staining solution (0.2% AgNO3, 0.076% 
Formalin), washed 2 × 1 min in H2O and developed in developing 
solution (6% Na2CO3, 0.05% Formalin, 0.0004% Na2S2O3) until 
desired bands intensity. The reaction was stopped by replacing 
developing solution with stop solution (50% MeOH, 12% HAc) and 
incubating for 5 min.
Immunoblotting
Cells transfected with mini-µ constructs were harvested by trypsina-
tion, counted and lysed either in RIPA buffer (1 ml per 106 cells; 
50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% SDS, 0.5% Na-deoxy-
cholate, 1 mM EDTA) or gentle hypotonic lysis buffer (1 ml per 106 
cells; 10 mM Tris-HCl, pH 7.5, 10 mM NaCl, 2 mM EDTA, 0.1% 
Triton X-100, 1× protease inhibitor cocktail [B14001; Biotool]). Cell 
lysates were clarified by centrifugation for 15 min at 16,100 × g, 4°C 
and supernatants were collected for further analysis. Cell equiva-
lents of (1–2) × 105 (8 × 105 for mini-µ reporter constructs) per lane in 
LDS sample buffer (NP0008; Thermo Fisher) or SDS sample buffer 
(60 mM Tris-HCl, pH 6.6, 100 mM DTT, 10% glycerol, 2% SDS, 
0.01% bromophenol blue), respectively, were loaded. The proteins 
were separated on a NuPAGE 4–12% Bis-Tris Midi Gel (Thermo 
Fisher Scientific) or on a 6% or 10% SDS–PAGE. Proteins separated 
with NuPAGE gels were transferred on a nitrocellulose membrane 
using the iBlot Gel Transfer System (Thermo Fisher) according to the 
manufacturer’s instructions. A TE77 ECL Semi-Dry Transfer Unit 
(Amersham Biosciences) was used to transfer proteins from a SDS–
PAGE on a nitrocellulose membrane (Optitran BA-S 85; Whatman). 
The HBB proteins separated with the NuPAGE gel as well as mini-µ 
reporter proteins were transferred on a 0.1 µm nitrocellulose mem-
brane (10600105; GE Healthcare) using the TE77 ECL Semi-Dry 
Transfer Unit. For the slot blot, 8 × 105 cell equivalents were loaded 
per well of a Bio-Dot SF Microfiltration Apparatus (170-6542; Bio-
Rad) and blotted on a 0.1 µm nitrocellulose membrane (10600105; 
GE Healthcare). Subsequently, membranes were blocked with 5% 
nonfat dry milk in 0.1% Tween in Tris-buffered saline (TBS), incu-
bated at 4°C overnight with the primary antibodies, washed with 
0.1% Tween in TBS, and incubated 1.5 h at room temperature with 
the fluorescence-labeled secondary antibodies. C-terminal trun-
cated SMG7 protein in clone fs15 (in Supplemental Figure S3C) was 
detected using the SuperSignal Western Blot Enhancer kit (46640; 
Thermo Fisher) according to the manufacturer’s instructions. The 
washed and dried membranes were analyzed using the Odyssey 
Infrared Imaging System (LI-COR).
Immunofluorescence staining
Twenty-four hours posttransfection, 4 × 104 cells were seeded per 
well of an eight-chamber slide (7647; Semadeni). Cells were fixed 
with 4% paraformaldehyde for 20 min at room temperature, washed 
3 × 5 min with TBS, permeabilized and blocked with 0.5% Triton 
X-100, 6% bovine serum albumin (BSA) in TBS for 30 min at room 
temperature. Afterward, cells were incubated with mouse anti-HA 
(sc-7392; Santa Cruz) diluted 1:1000 in 0.1% Triton X-100, 6% BSA 
in TBS at 4°C overnight. Subsequently, cells were washed 3 × 5 min 
with TBS and incubated for 2 h at room temperature with chicken 
anti-mouse IgG AF488 (A-21200; Thermo Fisher Scientific), diluted 
1:500 in 0.1% Triton X-100, 6% BSA, 100 ng/ml 4′,6-diamidin-2-phe-
nylindol in TBS. Before mounting with Vectashield Hardset mount-
ing medium (H-1400; Vector Laboratories), three final washing steps 
with TBS, 5 min each, were performed. Pictures were acquired with 
a DFC360 FX monochrome camera (Leica Biosystems) mounted on 
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empty pSUPuro. Two days after transfection, the two wells trans-
fected with the same plasmids were pooled on a 15 cm plate and 
puromycin (2 µg/ml) selection was conducted for 2 d. Colonies 
originating from single cells were picked and analyzed. RNA and 
genomic DNA were harvested from TRIzol. SMG7 expression was 
analyzed by RT-qPCR and the respective genomic locus was ampli-
fied by PCR using the Maximo Taq DNA Polymerase 2X-preMix 
(S113; GeneON) according to the manufacturer’s instructions. Prim-
ers are presented in the Supplemental Materials and Methods. PCR 
products were purified over a preparative agarose gel using the 
Wizard SV Gel and PCR Clean-Up System (A9281; Promega) and 
sent for Sanger sequencing (Barcode Economy Run Sequencing 
Service; Microsynth AG). To determine the genomic sequence of 
clones with different mutations in the two alleles, PCR products were 
TOPO-TA cloned into the pCRII-TOPO plasmid (K4610-20; Thermo 
Fisher) according to the manufacturer’s manual. Plasmids were sub-
sequently amplified and purified from single E.coli colonies and 
sent for sequencing.
Gene replacement of TDP-43 by DD-TDP-43 in hiPSCs
The first intron of the TARDBP gene was targeted using pCRISPR-
EF1a-SpCas9 TDP KO t2, coding for the sgRNA targeting the se-
quence 5′-CTGAAGGCTTATGATGCGTCAGG-3′ in the first intron 
of TARDBP together with a TDP-43 replacement matrix (General 
Biosystems). A 100 mm dish with 80% confluent hiPSCs was trans-
fected with 5 µg pCRISPR-EF1a-eSpCas9 (1.1) and 25 µg of the 
donor matrix. Cells were maintained in mTeSR1 containing 10 µM 
Y-27632 and 200 nM Shield1 ligand to stabilize DD-TDP-43 in 
case of successful genome editing. The transfection was repeated 
the next day. After the second transfection, cells were detached 
using Accutase and transferred onto a 150 mm dish. Positive 
clones were selected with puromycin (0.25 µg/ml) in mTeSR1 con-
taining 10 µM Y-27632 and 200 nM Shield1 ligand for 3 d. Y-27632 
(10 µM) was maintained for four more days until single cells grew 
to small colonies. Afterward, cells were maintained in mTeSR1 
containing 200 nM Shield1 ligand. Colonies originating from sin-
gle cells were picked. RNA and genomic DNA were extracted us-
ing TRIzol. TDP-43 and DD-TDP-43 expression were analyzed by 
RT-qPCR and the respective genomic locus was analyzed by PCR 
using the KAPA Taq ReadyMix (KK1006; KAPA Biosystems) ac-
cording to the manufacturer’s instructions. Used primers are pres-
ent in the Supplemental Materials and Methods. Positive clones 
were expanded and grown in the presence or absence of Shield1 
ligand (withdrawal of Shield1 ligand 24 h before harvest). Re-
placement of the endogenous protein was verified by Western 
blotting.
same strategy with some modifications. Briefly, six 80% confluent 
wells of a six-well plate with HeLa cells were each transfected with 
2 µg plasmid coding for the Cas9 endonuclease and the guide 
RNAs (3 × target A, 3 × target B) targeting the first intron of FUS 
(pU6gDNA-Cas9-GFP; target sequence A: 5′-TGGATGTCCACCAA-
GACCTTGG-3′ or target sequence B 5′-TCCAATGGTTAAGGC-
TTCTGGG-3′ [Sigma-Aldrich]) and 1 µg FUS KO ZeoR donor plasmid 
(General Biosystems). Four days after transfection, the two condi-
tions were pooled and zeocin selection was started (150 µg/ml) and 
maintained until analysis of clones originating from single cells for 
FUS expression by RT-qPCR. Positive clones were expanded and the 
absence of the protein was verified by Western blotting. Each well 
(six wells in total in a six-well plate) of 80% confluent hiPSCs was 
transfected with 2.5 µg plasmid coding for the Cas9 endonuclease 
and the guide RNAs (3 × target sequence A, 3 × target sequence B) 
and 5.5 µg FUS KO ZeoR donor plasmid. The transfections were re-
peated the day after. One day after the second transfection, cells 
were detached with Accutase (Thermo Fisher Scientific) to generate 
single cells. Cells were maintained in mTeSR1 containing 10 µM of 
the ROCK inhibitor Y-27632 (Stemcell Technologies) to enhance sin-
gle-cell survival. Two days later, zeocin selection (25 µg/ml) was 
started and maintained for 3 d. Colonies originating from single cells 
were picked and analyzed for FUS expression by RT-qPCR. Positive 
clones were expanded, and the absence of the FUS protein was veri-
fied by Western blotting.
Generation of SMG7 KO HT1080 cells by CRISPR-Trap 
and high-throughput sequencing
Six 90% confluent wells of a six-well plate with HT1080 cells were 
each transfected with 1.5 µg of the plasmid coding for the Cas9 
endonuclease and the guide RNA targeting the first intron of 
SMG7 (pU6gDNA-Cas9-GFP; target sequence: ACCAAACGTT-
GCCGGGCACGGGG) and 1.5 µg of the SMG7 KO ZeoR donor 
plasmid. Three days after transfection, the six wells were pooled 
and zeocin (500 µg/ml) selection was started and maintained until 
analysis of SMG7 expression by RT-qPCR in clones originating 
from single cells. Positive clones were expanded and the absence 
of the protein was verified by Western blotting. Wild-type (WT) 
HT1080 cells and two independent SMG7 KO clones were ana-
lyzed by high-throughput sequencing. The library was prepared 
with the Illumina TruSeq Stranded Total RNA Library Prep Kit 
(chemistry v3), which also includes a ribo-zero depletion step. The 
reads were produced by means of a HiSeq3000 machine, with a 
length of 100 base pairs and in single-end mode. The sequencing 
depth was around 85 million per sample. Every condition was ana-
lyzed in triplicate. The reads were mapped to the human genome 
(hg38) with the program HISAT2 (Kim et al., 2015). The genome 
index was created with the exon and splice site information taken 
from the Ensembl transcriptome annotation (release 84). The in-
sert sequence containing the resistance cassette was added to 
the SMG7 locus. The locus coverage was investigated by means 
of wig files.
Generation of SMG7 KO HT1080 cells by conventional 
CRISPR approach
Four 80% confluent wells of a six-well plate with HT1080 cells 
were each transfected with 2.8 or 4.8 µg of the plasmid coding 
for the Cas9 endonuclease and the guide RNA targeting either 
the third (pCRISPR-EF1a-Cas9-GFP Smg7 exon 3 t1; target se-
quence: 5′-GAAAATGCTAGTTACCGATTTGG-3′) or the 15th 
exon of SMG7 (pCRISPR-EF1a-Cas9-GFP Smg7 exon 15 t1; target 
sequence: 5′-GGAGTTACTTGCTTGAGTTGGGG-3′) and 200 ng 
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